Format

Send to

Choose Destination
See comment in PubMed Commons below
Prostate Cancer Prostatic Dis. 2014 Mar;17(1):23-7. doi: 10.1038/pcan.2013.37. Epub 2013 Dec 24.

Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.

Author information

1
1] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA [2] Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
2
Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
3
Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
4
1] Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA [2] Department of Genome Sciences, University of Washington, Seattle, WA, USA.
5
1] Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA [2] Department of Pathology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA [3] Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
6
1] Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA [2] Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

Abstract

BACKGROUND:

Comprehensive molecular characterization of cancer that has metastasized to bone has proved challenging, which may limit the diagnostic and potential therapeutic opportunities for patients with bone-only metastatic disease.

METHODS:

We describe successful tissue acquisition, DNA extraction, and whole-exome sequencing from a bone metastasis of a patient with metastatic, castration-resistant prostate cancer (PCa).

RESULTS:

The resulting high-quality tumor sequencing identified plausibly actionable somatic genomic alterations that dysregulate the phosphoinostide 3-kinase pathway, as well as a theoretically actionable germline variant in the BRCA2 gene.

CONCLUSIONS:

We demonstrate the feasibility of diagnostic bone metastases profiling and analysis that will be required for the widespread application of prospective 'precision medicine' to men with advanced PCa.

PMID:
24366412
PMCID:
PMC4364998
DOI:
10.1038/pcan.2013.37
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center